Qube Research & Technologies (QRT)’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-21,730
| Closed | -$98.4K | – | 3641 |
|
|
2025
Q3 | $98.4K | Sell |
21,730
-8,949
| -29% | -$26.4K | ﹤0.01% | 3068 |
|
|
2025
Q2 | $66K | Buy |
+30,679
| New | +$85.8K | ﹤0.01% | 3102 |
|
|
2024
Q3 | – | Sell |
-16,265
| Closed | -$112K | – | 3232 |
|
|
2024
Q2 | $112K | Sell |
16,265
-25,354
| -61% | -$236K | ﹤0.01% | 2584 |
|
|
2024
Q1 | $588K | Buy |
41,619
+41,547
| +57,704% | +$632K | ﹤0.01% | 2449 |
|
|
2023
Q4 | $540 | Sell |
72
-2,425
| -97% | -$22.1K | ﹤0.01% | 3912 |
|
|
2023
Q3 | $37.5K | Buy |
+2,497
| New | +$44.8K | ﹤0.01% | 2952 |
|
|
2022
Q4 | – | Sell |
-6,756
| Closed | -$64K | – | 2414 |
|
|
2022
Q3 | $64K | Sell |
6,756
-1,633
| -19% | -$21.5K | ﹤0.01% | 2080 |
|
|
2022
Q2 | $101K | Buy |
+8,389
| New | +$87.9K | ﹤0.01% | 1947 |
|
|
2021
Q4 | – | Sell |
-2,366
| Closed | -$51K | – | 2477 |
|
|
2021
Q3 | $51K | Buy |
+2,366
| New | +$60.4K | ﹤0.01% | 1872 |
|
|
2021
Q1 | – | Sell |
-1,144
| Closed | -$124K | – | 1871 |
|
|
2020
Q4 | $124K | Sell |
1,144
-1,971
| -63% | -$244K | ﹤0.01% | 1616 |
|
|
2020
Q3 | $321K | Buy |
+3,115
| New | +$466K | ﹤0.01% | 1214 |
|
Qube Research & Technologies (QRT)'s ADVM Position: Q4 2025 in Review
Qube Research & Technologies (QRT) sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 21,730 shares — an estimated $98.4K sold.
Qube Research & Technologies (QRT) first reported a position in ADVM in Q3 2020 and held it in 11 quarters. The position peaked at $588K in Q1 2024. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Qube Research & Technologies (QRT) reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Qube Research & Technologies (QRT) sold 21,730 Adverum Biotechnologies shares in Q4 2025, an estimated $98.4K.
- Qube Research & Technologies (QRT) first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 11 quarters.
- Qube Research & Technologies (QRT)'s Adverum Biotechnologies position peaked at $588K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.